OctoPlus N.V. has signed a feasibility agreement with a U.S.-based pharmaceutical company relating to the use of OctoPlus’ controlled release technology. OctoPlus will develop a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActive®. If the evaluation is successful, the companies may decide to enter into a full process development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclos...